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Abstract: The objective of this cross-sectional evaluation study was to compare data generated 
through prescriber assessments, and data generated from independent direct contact with 
opiate-dependent patients in ofﬁ  ce-based practice to evaluate buprenorphine treatment for 
modality of buprenorphine absorption, benzodiazepine use, and depressive symptoms. A group 
of buprenorphine ofﬁ  ce-based practice prescribers was selected to participate in this study. 
They were asked to screen for inclusion all their patients coming for a visit from February to 
August 2002. Once included by their prescribing physician, patients were given a series of 
self-administered questionnaires to be returned directly to the research staff, independently 
of their prescriber. Each prescriber was given a questionnaire to complete based on their 
knowledge and interview of the patient. Items assessed were history of current treatment, current 
substance use, buprenorphine treatment related behavior (daily frequency of intake, route of 
administration), benzodiazepine use and existence of a major depressive episode. Prescribers 
and patients’ questionnaires were compared. Concordance of both assessments was assessed by 
kappa statistics. The sensitivity and speciﬁ  city as well as the positive and negative predictive 
values of prescriber collected information were compared to that of their patients’. There was 
an overall good correlation between both data sources on the procedures for buprenorphine use 
especially for intravenous use of buprenorphine. There were important variations: obtaining 
buprenorphine without a prescription or with a prescription made by another doctor, intravenous 
administration of buprenorphine, use of benzodiazepines, and depression were underestimated 
by prescribers.
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Introduction
Since medical doctors in France have been allowed to prescribe buprenorphine for the 
treatment of opiate-dependent patients, it is estimated that 20% of them have prescribed 
this medication (OFDT 2004). Most of them treat less than 5 patients simultaneously. 
Data from comparative clinical trials in the literature show that buprenorphine gives 
similar results to those of methadone (Mattick et al 2003; Gerra et al 2004) when 
controlling for dosage and induction issues. Numerous studies are now available 
(Auriacombe et al 2004; Fatseas and Auriacombe 2007) and several indicators report 
a positive impact of this treatment as it is provided in France (Vignau and Brunelle 
1998; OFDT 2003; Costes et al 2004). These are either descriptive cross-sectional 
studies of patients receiving buprenorphine treatment (Bouchez and Vignau 1998; 
Vignau and Brunelle 1998; Damon et al 2001; Vignau et al 2001; Thirion et al 2002) 
or studies comparing patients at the initiation of buprenorphine treatment and several Patient Preference and Adherence 2008:2 370
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months later (De Ducla et al 2000; Duburcq et al 2000; Fhima 
et al 2001). Other studies, concerning in particular patients 
attending specialized addiction centers (Thirion et al 1999, 
2001; Barrau et al 2001), or participating in syringe-exchange 
programs (Moatti et al 2001; Obadia et al 2001; Valenciano 
et al 2001) have reported the existence of inappropriate use 
of buprenorphine by the nasal or intravenous route, as well 
as “doctor-shopping” behavior. These reports of misuse 
are not in themselves a surprise and it was reasonable to 
expect them (Auriacombe 2005). As many untreated opiate-
dependent patients use their opiate of choice by the venous 
or nasal route, it was reasonable to expect to ﬁ  nd a certain 
number of treated patients continuing to use these routes of 
administration.
The combination of buprenorphine with benzodiazepines 
is generally not recommended as it may lead to severe respira-
tory depression (VIDAL 2004). However, in practice, the use 
of benzodiazepines is very frequent in buprenorphine-treated 
patients (13% to 47% of subjects) (OFDT 2004). Among 
these patients, benzodiazepines may be abused and lead to 
misuse (excess dosages, off-prescription use, etc).
In such a context, it is important to know if doctors 
managing buprenorphine-treated patients are capable of 
identifying these predictable problems, in order to provide an 
appropriate therapeutic response. This question is particularly 
important within the French context as most of the doctors 
concerned are not addiction specialists and have minimal 
training and limited experience.
In some studies, depression was reported as a possible 
risk factor for use by the intravenous route and sharing of 
drug-injection equipment among opiate-dependent patients 
(Metzger et al 1991a, 1991b; Bertorelle et al 2000; Carrieri 
et al 2003). This could be a risk factor for buprenorphine 
misuse especially because studies have shown that depression 
is frequently under-diagnosed by general practioners (Nabarro 
1984; Rodin and Voshart 1986; Katon 1987; Schulberg and 
Burns 1988; Lepine 1994; Weissman et al 1996; Lepine et al 
1997; Tylee et al 1999a, 1999b).
The objective of this study was to assess the degree of 
agreement in an ofﬁ  ce-based setting between the data directly 
generated by buprenorphine-treated patients and the doctors’ 
knowledge and perceptions about these same patients on a 
number of predetermined variables. In addition to informa-
tion concerning the modalities of buprenorphine treatment, 
combination with benzodiazepines and misuse practices, we 
also investigated the existence of depressive episodes. We 
checked the validity of the information collected from doctors 
and compared with that collected from patients.
Methods
Study design
This was a cross-sectional study of buprenorphine-treated 
patients and their prescribing doctors carried out in France 
from February to August 2002.
Sampling procedure
France was divided into 35 zones containing equivalent 
numbers of buprenorphine prescribers on the basis of 
buprenorphine sales in the indication of severe opiate depen-
dence. One hundred general practitioners were randomly 
selected and solicited in each of these zones. After ﬁ  rst 
receiving an information letter about the study, doctors were 
contacted by telephone until 20 doctors had been recruited 
per zone. Participating doctors were given the necessary 
instructions for the inclusion of patients and collection of 
information. Doctors were asked to include consecutively 
over a one month period all patients to whom they prescribed 
buprenorphine, however long was the history of treatment. 
They could include a maximum of 25 patients.
Data collection procedure
The doctors gave each participating patient an envelope 
containing an explanatory letter about the study, a consent 
form and an anonymous self-questionnaire to be ﬁ  lled out. 
The patient had to answer the questionnaire at home and 
return it in a pre-stamped addressed envelope provided for 
this purpose. For his part, the doctor had to ﬁ  ll in an anony-
mous questionnaire for each included patient. In order to ﬁ  ll 
in this questionnaire, the doctor had to base his/her responses 
on data in the patient’s medical ﬁ  les and his/her own knowl-
edge about each patient. Pairing of prescriber questionnaires 
with patient self-questionnaires was conducted a posteriori 
from the order numbers. The doctor had to note on each ques-
tionnaire he ﬁ  lled out the number on the self-questionnaire 
given to the corresponding patient.
Variables collected
The following information was collected on the two 
questionnaires: sociodemographic variables (age, gender, 
source of income, place of residence), information about 
buprenorphine-treatment procedures, benzodiazepine use and 
the existence of depression. Information on buprenorphine 
usage investigated previous use before current treatment, 
the obtaining of buprenorphine during the last month from 
one or more other doctors, the intravenous or nasal use of 
buprenorphine currently or in the past, as well the use of 
buprenorphine in divided doses several times a day.Patient Preference and Adherence 2008:2 371
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Three variables were not collected in a strictly similar 
way with the two questionnaires. Concerning the splitting of 
the buprenorphine dose several times a day, the patient had 
to mention if he had divided the last dose of buprenorphine, 
whereas the doctor had to indicate the number of daily doses 
prescribed on the patient’s last prescription. For benzodiaz-
epine use during the last month, patients had to indicate if 
the benzodiazepines that he/she had taken during the last 
month were prescribed by the doctor who had given them 
the questionnaire, whereas doctors had to note if benzodi-
azepines had been prescribed to the patient during the last 
month, which did not necessarily mean that the patient had 
effectively taken them. Different collection procedures were 
used to detect the occurrence of a depressive episode during 
the last month. The patient had to answer the “depressive 
episode” section of the Mini International Neuropsychiatric 
Interview (MINI) questionnaire (Sheehan et al 1998). This 
questionnaire is a tool for establishing a clinical diagnosis 
according to the International Classiﬁ  cation of Diseases 
10th edition (ICD-10) (Organisation Mondiale de la Santé 
1993) and the Diagnostic and Statistical Manual of mental 
disorders version IV of the American Psychiatric Association 
(DSM-IV) (APA 1996). For this study, the ICD-10 version 
of the MINI was used for self-rating. The doctor, on the 
other hand, had to report the absence, probable presence or 
effective presence of symptoms of depression in the patient 
during his usual clinical examination.
The understandability of the patient questionnaire was 
tested beforehand on ten volunteer patients, in the presence 
of an investigator. After ﬁ  lling in the questionnaire, the 
investigator made sure that each question had been perfectly 
understood and noted any of the patients’ suggestions. This 
preliminary test showed an excellent understanding by 
patients. In addition, 49 patients answered the questionnaire 
in front of an independent investigator a few days after ﬁ  lling 
in the questionnaire on their own. No statistically signiﬁ  cant 
difference was found between the patients’ responses by 
these two self-reporting methods.
Analysis strategy
The doctors’ responses were re-coded as variables with three 
levels: “yes”, “no”, “don’t know”. It should be noted that only 
the doctor had the opportunity of answering “don’t know”, 
whereas the patient had to answer all questions by either 
“yes” or “no”. Missing data were coded “no answer”.
A description of the data collected by doctors and 
patients was ﬁ  rst made. The distribution of the variables was 
described by their frequencies.
Secondly, the degree of concordance between the 
doctors’ and patients’ responses was analysed by using the 
kappa statistic (Cohen 1960; Byrt et al 1993), for variables 
collected in a similar way with the two questionnaires. 
The value of kappa varies between −1 (total disagreement 
between the two responses), 0 (independence of responses) 
and +1 (total agreement between the two responses). Above 
0.80, concordance is considered to be excellent, between 
0.61 and a 0.80 it is considered good, between 0.41 and 
a 0.60 moderate, between 0.21 and a 0.40 poor and below 
0.21 bad (Landis and Koch 1977). This analysis of concor-
dance was not carried out for three variables, divided dose 
of buprenorphine, use of benzodiazepines and diagnosis of 
depression, since these were not collected in a similar way 
by the two questionnaires.
Finally we studied the validity of the doctors’ responses 
in relation to those of the patients for all variables. For each 
doctor-patient pair we used the information provided by 
patients in their responses to the self-questionnaire as refer-
ence. The sensitivity and speciﬁ  city of the doctors’ responses 
were calculated. The sensitivity evaluated the capacity of the 
doctor to correctly detect patient practices. The sensitivity 
of the doctor’s response for a given question was deﬁ  ned as 
the proportion of afﬁ  rmative responses by doctors among all 
the afﬁ  rmative responses of patients to the same question. 
The speciﬁ  city evaluated the capacity of doctors to correctly 
detect patients who did not have the practices for which they 
were questioned. The speciﬁ  city of the doctor’s response for 
a given question was deﬁ  ned as the proportion of negative 
responses of the doctors among all the negative responses 
of the patients for the same question. We also calculated 
the positive and negative predictive values of the doctor’s 
responses. The positive predictive value (PPV) represented, 
for a given practice, the proportion of patients who really pre-
sented this practice among the cases reported by the doctor. 
The PPV was deﬁ  ned as the probability that the patient 
gave an afﬁ  rmative response when the doctor also gave an 
afﬁ  rmative response. The negative predictive value (NPV) 
represented, for a given practice, the proportion of patients 
who did not present this practice among the cases that the 
doctor reported as not presenting it. The NPV was deﬁ  ned as 
the probability that the patient answered by a negative when 
the doctor also gave a negative response.
Statistical analysis of the whole database was ﬁ  rst carried 
out by the Louis Harris Medical Institute, with COSI 4.11® 
software (MLI, France) and DAG Stat® software for measure-
ments of Kappa (Mackinnon 2000). Validity analyses were 
conducted by the Laboratoire de Psychiatrie of the Université Patient Preference and Adherence 2008:2 372
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Victor Segalen Bordeaux 2, using the database provided by 
Louis Harris Medical Institute and SAS statistical software 
(version 8.2; SAS institute, Inc., Cary, NC, USA).
Results
A total of 460 doctors took part in the study. Doctors ﬁ  lled in 
2547 questionnaires and 1289 self-questionnaires were sent 
back by the patients. Out of these 1289 self-questionnaires, 
1172 could be matched with a doctor questionnaire. This 
was because doctors did not return the questionnaire corre-
sponding to the patients whom they included for 117 patient 
questionnaires. We compared the doctor questionnaires of 
patients who returned the self-questionnaire (n = 1172) with 
those of the patients who did not return the self-question-
naire (n = 1375), on the basis of general characteristic (age, 
gender, dosage of buprenorphine, history of treatment, 
etc). This comparison showed that there was no signiﬁ  cant 
difference between responding and nonresponding patients 
for those variables.
Description of the sample and distribution 
of responses in each questionnaire
Most of the patients were male (72.9 %). The average age 
was 33 years. More than half of the patients (56.1 %) had a 
regular or occasional salaried job, and 68.4 % were tenants 
or owners of their home (Table 1).
Missing data (“no answer”) were more frequent among 
patients than doctors (Table 2). The frequency of “don’t 
know” responses by doctors ranged from 0 to a little more 
than 17% depending on the question. The most frequent 
doctor “don’t knows” concerned (1) the use of buprenor-
phine without a prescription before the current medical 
treatment, (2) use of buprenorphine by the nasal route life-
time and during the past 30 days and (3) the prescription 
of buprenorphine by another doctor before current medical 
treatment.
With regard to the frequencies of afﬁ  rmative responses, 
the doctors underestimated the practices declared by their 
patients for almost all variables. Two variables were 
exceptions however: prescription of buprenorphine by 
another doctor before the current treatment and prescription 
of benzodiazepines during the last month by the doctor 
prescribing the buprenorphine, which were over-estimated 
by doctors (Table 2).
Analysis of the concordance of responses
The questions for which there was a good agreement were: 
obtaining of buprenorphine without prescription during the 
Table 1 General characteristics of subjects in the sample. 
Cross-sectional study of buprenorphine-treated patients and their 
prescribing doctors France, 2002 (n = 1172)
n%
Men 854 72.9
Age
   25 years. 123 10.5
  25 to 29 years 209 17.8
  30 to 34 years 315 26.9
  35 to 39 years 252 21.5
  40 years 191 16.3
 NA1 82 7.0
Source of income2
 Regular  salary 517 44.1
  Occasional salaried work 141 12.0
  Moonlighting (nondeclared work) 77 6.6
  Minimum income allocation (RMI) 282 24.1
 Unemployment  beneﬁ  t 135 11.5
 Sickness/disability  allowance 66 5.6
 None 13 1.1
 Other 67 5.7
 NA 28 2.4
Place of residence
  Owner or tenant 802 68.4
 Parents 239 20.4
 Friends 36 3.1
 Hotel 12 1.0
 Squat 16 1.4
 Other 41 3.5
 NA 26 2.2
Notes: 1No answer; 2Several possible answers.
last month, obtaining of buprenorphine prescribed by another 
doctor during the last month, intravenous use of buprenor-
phine during the last month (Table 3). The questions for 
which there was a moderate agreement were: prescription 
of buprenorphine by another doctor before treatment by the 
current doctor, life-time intravenous use of buprenorphine, 
use of buprenorphine by the nasal route during the last month, 
use of buprenorphine without prescription before treatment 
by the current doctor. Finally the question for which there 
was a poor agreement was life-time use of buprenorphine by 
the nasal route (Table 3).
Sensitivity and speciﬁ  city 
of the doctors’ responses
The two questions for which the sensitivities of the doctors’ 
responses were the highest (80.5% and 73.6%, respectively) Patient Preference and Adherence 2008:2 373
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Table 2 Description of data obtained from doctors and reported by the patients in the self-questionnaire. Cross-sectional study of 
buprenorphine-treated patients and their prescribing doctors France, 2002 (n = 1172)
Patient Doctor
n%n %
Prescription of buprenorphine 
by another doctor before 
treatment by current doctor
No 
Yes 
NA1
DK2
693
453
26
–
59.1
38.7
2.2
–
586
495
7
84
50.0
42.2
0.6
7.2
Took buprenorphine without 
prescription before current doctor
No
Yes
NA
DK
710
432
30
–
60.6
36.9
2.6
–
565
369
35
203
48.2
31.5
3.0
17.3
Obtained buprenorphine by 
co-prescription during last month
No
Yes 
NA
DK
951
206
15
–
81.1
17.6
1.3
–
1021
103
36
12
87.1
8.8
3.1
1.0
Obtained buprenorphine without 
prescription during last month
No
Yes
NA
DK
980
170
22
–
83.6
14.5
1.9
–
1042
89
3
38
88.9
7.6
0.3
3.2
Life-time intravenous injection 
of buprenorphine 
No
Yes
NA
DK
664
491
17
–
56.6
41.9
1.5
–
696
409
4
63
59.4
34.9
0.3
5.4
Intravenous injection of 
buprenorphine during last month
No
Yes
NA
DK
937
190
45
–
79.9
16.2
3.8
–
990
139
8
35
84.5
11.9
0.7
3.0
Life-time use of buprenorphine 
by the nasal route
No
Yes
NA
DK
631
522
19
–
53.8
44.5
1.6
–
751
306
0
115
64.1
26.1
0.0
9.8
Use of buprenorphine by nasal route 
during last month
No
Yes
NA
DK
921
179
72
–
78.6
15.3
6.1
–
959
110
7
96
81.8
9.4
0.6
8.2
Depression3 No
Yes
NA
DK
612
557
3
–
52.2
47.5
0.3
–
640
477
55
0
54.6
40.7
4.7
0.0
Prescription of benzodiazepines 
during last month by the doctor 
prescribing buprenorphine
No
Yes
NA
DK
918
240
14
–
78.3
20.5
1.2
–
876
283
13
0
74.7
24.1
1.1
0.0
Obtained benzodiazepines from 
another doctor or without 
prescription during the last month
No
Yes
NA
DK
955
203
  14
–
81.5
17.3
1.2
–
1010
87
14
61
86.2
7.4
1.2
5.2
Buprenorphine taken in splitted 
doses during the day4
No
Yes
NA
DK
554
590
28
–
47.3
50.3
2.4
–
834
331
7
0
71.2
28.2
0.6
0.0
Notes: 1No answer = missing data; 2Answered “don’t know”; 3“Yes” doctors = “yes + probable”; 4Last splitted dose for the patient vs splitted doses prescribed by doctor. Patient Preference and Adherence 2008:2 374
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were prescription of buprenorphine by another doctor before 
the current treatment and prescription of benzodiazepines by 
the doctor who provided the questionnaire during the last 
month (Table 4).
The speciﬁ  city of the doctors’ responses was higher than 
67% for all the questions. The two questions with the high-
est speciﬁ  cities were intravenous injection of buprenorphine 
during the last month and use of buprenorphine without 
prescription during the last month (95.2% and 94.8%, 
respectively).
Three behaviors were misidentiﬁ  ed by doctors (sensitivity 
lower than 30%): obtaining buprenorphine by co-prescription 
during the last month (reported by 17.6% of patients), obtain-
ing buprenorphine without prescription during the last month 
(reported by 14.5% of the patients) and use of buprenorphine 
by the nasal route during the last month (reported by 15.3% 
of the patients) (Tables 2 and 4).
The sensitivity of doctors for detection of a depressive 
disorder was poor, even when probable cases were re-rated 
as conﬁ  rmed cases (Table 4). Only a little more than half 
of the patients (52.5%) detected as having a “probable” 
depressive disorder by the doctor really presented a depres-
sive episode according to the MINI. More important, 39.3% 
of patients not presenting a depressive disorder according 
to the doctor fulﬁ  lled the MINI criteria of a depressive 
episode (Table 5).
Predictive values of the doctors’ 
responses
The variables with the highest PPV were splitting of 
buprenorphine doses during the day, prescription of 
buprenorphine by another doctor before the current treatment 
and use of buprenorphine without a prescription before the 
current treatment (Table 4). The variables with the highest 
NPV were prescription of benzodiazepines during the last 
month by the doctor who provided the questionnaire, obtaining 
of buprenorphine without prescription during the last month 
and nasal use of buprenorphine during the last month.
Discussion
The objective of this study was to assess the level of 
concordance between the information collected directly 
from buprenorphine treated patients and the knowledge 
and perceptions of doctors about the procedures for use of 
buprenorphine, benzodiazepine use and the existence of a 
depressive disorder. Our study sample included 1172 doctor-
patient pairs. The results showed that there was an overall 
satisfactory concordance between the responses provided by 
patients and doctors on the procedures for buprenorphine use. 
However, some behaviors of a minority of patients did not 
seem to be correctly identiﬁ  ed by the doctors.
Less than half the patients included by the doctors 
returned the questionnaire. The general characteristics of 
responder patients did not differ signiﬁ  cantly from those 
of nonresponders. However, although the response rate of 
patients was satisfactory (approximately 50%), the high 
proportion of nonresponders may have biased the concor-
dance results. For instance, patients who did not respond 
to the questionnaire may have been less involved in their 
treatment so that their doctor had a less good knowledge of 
their practices. This selection bias may have led to an over-
estimation of the concordance between the doctors’ and 
patients’ responses. Likewise, approximately two thirds of 
doctors solicited took part in the study. We have no infor-
mation about the reasons why doctors failed to participate. 
However, this did not seem to be due to a refusal since the 700 
solicited doctors (20 per zone) had initially accepted to take 
part. It may be that certain doctors lacked the time or moti-
vation to return the questionnaires. As for the patients, the 
study could have excluded doctors who were less involved 
in the management of buprenorphine-treated patients. 
Table 3  Agreement between doctors’ responses and the information 
reported by patients on self-questionnaires. Cross-sectional study of 
buprenorphine-treated patients and their prescribing doctors France, 
2002 (n = 1172)
Kappa Proportion
of concordant
results %
Obtained buprenorphine without 
prescription during last month
0.69 84
Obtained buprenorphine by
co-prescription during last month
0.62 81
Intravenous injection of buprenorphine 
during last month
0.61 81
Prescription of buprenorphine by 
another doctor before treatment by 
current doctor
0.57 78
Life-time intravenous injection
of buprenorphine
0.56 78
Use of buprenorphine by nasal
route during last month
0.56 78
Administration of buprenorphine 
without prescription before current 
doctor1
0.42 71
Life-time use of buprenorphine
by nasal route
0.38 69
Note: 1Among patients who have already taken buprenorphine in the past. Patient Preference and Adherence 2008:2 375
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Perhaps these doctors lacked information about their patients 
and this would also have resulted in an over-estimation of 
the agreement between the doctors’ and patients’ responses 
in our sample.
In our study, we chose to test the sensitivity and speciﬁ  c-
ity of the information collected by the doctors compared to 
the information given by patients. We therefore made the 
hypothesis that patients provide more accurate responses 
when they respond independently from their prescribing 
doctor. Patients may hide certain forms of misuse from their 
doctor in order to meet expectations, and therefore avoid the 
risk that doctors change their treatment.
The sensitivity of doctors to detect a depressive disorder 
identiﬁ  ed by the MINI was bad. Even in the best case for 
a high sensitivity (when probable cases were considered to 
present a depressive disorder), the doctors only detected 
slightly more than one depressive patient out of two. The 
MINI alone cannot conﬁ  rm a valid diagnosis of depres-
sion. Some authors have underlined the potential discrep-
ancy between what the MINI questionnaire measures and 
a diagnosis of depression established by a psychiatrist 
(Duburcq et al 1999). In particular, the speciﬁ  city of the 
MINI questionnaire is not very good so that it will tend to 
over-estimate the prevalence of depressive disorders.
It is possible, however, that doctors underestimate the 
incidence of depressive disorders among dependent patients, 
as they do with their other patients. Studies have shown 
that in the general population, a large number of depressive 
disorders were not detected by general practitioners (Nabarro 
1984; Rodin and Voshart 1986; Katon 1987; Schulberg and 
Burns 1988; Lepine 1994; Weissman et al 1996; Lepine et al 
1997; Tylee et al 1999a, 1999b). Finally, depressive disorders 
may change over time and may not be detected at a given 
time. These results must encourage doctors to better evaluate 
and more systematically seek the existence of depressive 
disorders in their patients.
The questions about buprenorphine administration during 
the last month (obtaining buprenorphine without a prescrip-
tion or with a prescription made by another doctor and intra-
venous administration) had a good concordance. However, 
the sensitivity of the doctors’ responses about these practices 
was poor. This shows that the doctors misidentiﬁ  ed patients 
who get buprenorphine by other means than their prescrip-
tion, just as they only detect one out of two patients who 
Table 4  Validity of the doctors’ responses compared to data in patient self-questionnaires. Cross-sectional study of buprenorphine-treated 
patients and their prescribing doctors France, 2002 (n = 1172)
Sensitivity
%
Speciﬁ  city
%
PPV1
%
NPV2
%
n
Prescription of buprenorphine by another 
doctor before treatment by current doctor3
80.5 74.5 84.3 69.3 677
Administration of buprenorphine without 
prescription before current doctor3
68.5 74.9 80.3 61.3 577
Obtained buprenorphine by co-prescription 
during last month
22.6 93.6 43.7 84.7 1109
Obtained buprenorphine without 
prescription during last month
23.8 94.8 44.3 87.8 1110
Life-time intravenous injection of buprenorphine  67.8 85.6 77.8 78.2 1088
Intravenous injection of buprenorphine 
during last month
51.6 95.2 77.7 78.2 1088
Life-time use of buprenorphine by nasal route  47.7 86.3 74.2 66.7 1040
Use of buprenorphine by nasal route 
during last month
29.6 93.1 45.3 87.3 1004
Depression4
 “Probables”  classed  “yes” 53.1 67.0 59.8 60.7 1114
 “Probables”classed  “no” 29.5 86.7 67.2 57.1 1114
 “Probables”  excluded 38.6 83.4 67.2 60.7 874
Prescription of benzodiazepines during the last 
month by the doctor prescribing buprenorphine
73.6 88.9 63.5 92.7 1145
Buprenorphine taken in splitted doses 
during the day
46.9 91.8 85.9 61.9 1137
Notes: 1Positive predictive value; 2Negative predictive value; 3Among patients who already took buprenorphine in the past; 4See Table 5 for details.Patient Preference and Adherence 2008:2 376
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inject buprenorphine. Patients concerned by these practices 
may have a tendency to hide it from their doctor, even when 
interviewed by him/her. On the contrary, the speciﬁ  city con-
cerning these questions was very good. This means that the 
doctor knew when patients were not concerned by these prac-
tices. Most of the patients in the sample were not concerned 
with these practices since only approximately one third of 
the subjects were involved each time. This probably explains 
the good concordance observed as the calculation of kappa 
takes into account the concordance for positive responses and 
also for negative responses. Here, it is the good agreement 
between the patients’ and doctors’ negative responses that 
inﬂ  uenced the total concordance.
Another practice that was largely underestimated by the 
doctors was the use of buprenorphine by the nasal route. 
Moreover, many doctors were unable to say if their patients 
used this route of administration, as the number of “don’t 
knows” was one of the highest. However, the administra-
tion of buprenorphine by the nasal route concerned close to 
one patient out of six in our sample. This practice is seldom 
documented in studies on buprenorphine treatment unlike the 
intravenous use of buprenorphine. This lack of information 
may explain why the doctors do not think about questioning 
their patients on this subject. It is also possible that this is a 
more recent modality of buprenorphine use. It is important 
to make health professionals aware of this practice. Doctors 
must discuss this question with their patients and inform 
them about the necessary conditions for treatment efﬁ  cacy 
and the risks of misuse.
The use of benzodiazepines without a prescription seemed 
to be underestimated by the doctors, either because they did 
not sufﬁ  ciently question their patients about this point, or 
because the patients preferred to hide this use. However, no 
calculation of concordance or sensitivity/speciﬁ  city could 
be conducted on this variable, as the questions were not 
formulated to permit this.
There was one very surprising result. Almost one third of 
the doctors in this study stated that they prescribed a splitting 
of daily dosing for buprenorphine whereas all recommenda-
tions state that buprenorphine must be given in a single daily 
dose or even once every two days. This is clearly stated in 
the French Summary of Product Characteristics in the Vidal® 
dictionary (VIDAL 2004) and all other European, American, 
and Australian buprenorphine treatment recommendations 
to doctors. Of notice, similar results were obtained in 1996 
in a follow-up study of patients treated by buprenorphine 
in France from healthcare networks (De Ducla et al 2000). 
Data in that study were collected retrospectively from 
general practitioners. Approximately one third of doctors 
declared that they prescribed splitting of daily dosage of 
buprenorphine to their patients even after induction and 
stabilization. At the time, this was considered to be related 
to lack of knowledge and experience. According to authors, 
this practice resulted from an unjustiﬁ  ed fear that the duration 
of action of buprenorphine is less than 24 hours due to its 
short half-life. In some French language publications on 
buprenorphine treatment, the term “splitting of dispensing” 
( fractionnement in French), is used, wrongly, in lieu of “daily 
dispensing” which is recommended at the start of treat-
ment, versus “weekly dispensing”. This misuse of language 
may cause confusion and suggest that splitting of the daily 
buprenorphine dose is recommended at the start of treatment. 
It should be underlined that a single daily dose is important 
to obtain a lasting and optimal effect that is essential for 
treatment efﬁ  ciency.
To conclude, the analysis of the concordance between the 
information collected by doctors and self-questionnaires ﬁ  lled 
in by patients shows that overall doctors have satisfactory 
information about how their patients use buprenorphine. The 
results also showed however that doctors missed those few 
patients that used buprenorphine intranasaly, off-prescription 
use of benzodiazepines and depressive disorders. Finally, 
it was found that nearly one third of the doctors prescribed 
buprenorphine using a splitting of daily dosing contrary to 
all recommendations. The doctors recruited for this study 
were general practitioners in ofﬁ  ce-based practice. It would 
be of interest to know if the concordance would have been 
better if addiction specialist doctors in treatment centers were 
questioned. It would be interesting to conduct the same study 
with doctors practicing in specialized addiction treatment 
centers to fully understand the signiﬁ  cance and complete 
implications of the results of this study.
Table 5 Depressive episodes among patients during the last 
month. Comparison of self-rating with MINI and doctor’s evalua-
tion. Cross-sectional study of buprenorphine-treated patients and 
their prescribing doctors France, 2002 (n = 1114*)
Patient evaluation with MINI
Doctor Total Depressive Nondepressive
n% n % n %
Yes 235 100 158 67.2 77 32.8
No 639 100 251 39.3 388 60.7
Probable 240 100 126 52.5 114 47.5
Total 1114 100 535 48.0 579 52.0
Note: *Exclusion of missing data and “don’t knows”.Patient Preference and Adherence 2008:2 377
Comparison of prescriber evaluations and patient-directed self-reports in buprenorphine-treated patients
From a clinical and treatment perspective, the results of 
this study show that doctors prescribing buprenorphine may 
have a good knowledge of their patient’s behavior regarding 
their treatment. They lack a good detection of depression, but 
this would seem to be a general characteristic of doctors in 
general practice and not speciﬁ  c to buprenorphine prescribers 
or related patients.
From the perspective of research, this study stresses on 
the importance of avoiding to collect data about patients 
from their treating doctors and possibly other related staff 
and to prefer speciﬁ  c research interviews in studies that 
have as an objective to evaluate patient behavior in treat-
ment settings.
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